| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial
|
Sirohi, B.
|
|
|
21 |
8 |
p. 1623-1629
|
artikel
|
| 2 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
|
Verhoeff, J.J.C.
|
|
|
21 |
8 |
p. 1723-1727
|
artikel
|
| 3 |
Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
|
Storey, D.J.
|
|
|
21 |
8 |
p. 1657-1661
|
artikel
|
| 4 |
Citrulline-based assessment score: first choice for measuring and monitoring intestinal failure after high-dose chemotherapy
|
Herbers, A.H.
|
|
|
21 |
8 |
p. 1706-1711
|
artikel
|
| 5 |
Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events
|
Kato, H.
|
|
|
21 |
8 |
p. 1699-1705
|
artikel
|
| 6 |
D-dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecologic cancer
|
Kodama, J.
|
|
|
21 |
8 |
p. 1651-1656
|
artikel
|
| 7 |
Editorial board
|
|
|
|
21 |
8 |
p. ii-iii
|
artikel
|
| 8 |
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
|
O'Day, S.J.
|
|
|
21 |
8 |
p. 1712-1717
|
artikel
|
| 9 |
ESMO Clinical Practice Guidelines: development, implementation and dissemination
|
|
|
|
21 |
8 |
p. 1736
|
artikel
|
| 10 |
Feasibility of sentinel lymph node biopsy in multiple unilateral synchronous breast cancer: results of a French prospective multi-institutional study (IGASSU 0502)
|
Giard, S.
|
|
|
21 |
8 |
p. 1630-1635
|
artikel
|
| 11 |
FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer
|
Marmé, F.
|
|
|
21 |
8 |
p. 1636-1642
|
artikel
|
| 12 |
First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham–Stout) with bevacizumab in a child
|
Grunewald, T.G.P.
|
|
|
21 |
8 |
p. 1733-1734
|
artikel
|
| 13 |
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma
|
Tsavachidou-Fenner, D.
|
|
|
21 |
8 |
p. 1599-1606
|
artikel
|
| 14 |
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors
|
Barlési, F.
|
|
|
21 |
8 |
p. 1682-1686
|
artikel
|
| 15 |
In this issue
|
|
|
|
21 |
8 |
p. 1567
|
artikel
|
| 16 |
Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
|
Bergmann, L.
|
|
|
21 |
8 |
p. 1573-1578
|
artikel
|
| 17 |
Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?
|
Tsujino, K.
|
|
|
21 |
8 |
p. 1668-1674
|
artikel
|
| 18 |
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma
|
Antoun, S.
|
|
|
21 |
8 |
p. 1594-1598
|
artikel
|
| 19 |
Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience
|
Gillessen, S.
|
|
|
21 |
8 |
p. 1589-1593
|
artikel
|
| 20 |
Management of isolated nonresectable liver metastases in colorectal cancer patients: a case–control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy
|
van Iersel, L.B.J.
|
|
|
21 |
8 |
p. 1662-1667
|
artikel
|
| 21 |
Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma
|
Kawai, Y.
|
|
|
21 |
8 |
p. 1612-1617
|
artikel
|
| 22 |
Monitoring of circulating tumor cells in a patient with synchronous metastatic melanoma and colon carcinoma
|
Fusi, A.
|
|
|
21 |
8 |
p. 1734-1735
|
artikel
|
| 23 |
Myocardial infarction and other major vascular events during chemotherapy for testicular cancer
|
Dieckmann, K.-P.
|
|
|
21 |
8 |
p. 1607-1611
|
artikel
|
| 24 |
Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients
|
He, L.-R.
|
|
|
21 |
8 |
p. 1675-1681
|
artikel
|
| 25 |
Patients with advanced non-seminomatous germ-cell tumour: the art of the start
|
Honecker, F.
|
|
|
21 |
8 |
p. 1569-1571
|
artikel
|
| 26 |
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
|
Shah, G.D.
|
|
|
21 |
8 |
p. 1718-1722
|
artikel
|
| 27 |
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
|
Massard, C.
|
|
|
21 |
8 |
p. 1585-1588
|
artikel
|
| 28 |
Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias
|
You, B.
|
|
|
21 |
8 |
p. 1643-1650
|
artikel
|
| 29 |
Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer
|
Karachaliou, N.
|
|
|
21 |
8 |
p. 1729-1730
|
artikel
|
| 30 |
Reply to Retrospective evaluation of cetuximab-related adverse events from claims databases—methodological concerns
|
Foley, K.A.
|
|
|
21 |
8 |
p. 1732-1733
|
artikel
|
| 31 |
Retrospective evaluation of cetuximab-related adverse events from claims databases—methodological concerns
|
Maier, S.
|
|
|
21 |
8 |
p. 1731-1732
|
artikel
|
| 32 |
Risk-adapted FDG–PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
|
Petrausch, U.
|
|
|
21 |
8 |
p. 1694-1698
|
artikel
|
| 33 |
Single-agent carboplatin AUC10 for metastatic seminoma with IGCCCG good prognosis disease; a feasibility study of the Orchid Clinical Trials Group
|
Matakidou, A.
|
|
|
21 |
8 |
p. 1730-1731
|
artikel
|
| 34 |
Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|
|
|
|
21 |
8 |
p. 1736
|
artikel
|
| 35 |
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency
|
Khan, G.
|
|
|
21 |
8 |
p. 1618-1622
|
artikel
|
| 36 |
Table of Contents
|
|
|
|
21 |
8 |
p. iv-v
|
artikel
|
| 37 |
Technical validation of an autoantibody test for lung cancer
|
Murray, A.
|
|
|
21 |
8 |
p. 1687-1693
|
artikel
|
| 38 |
Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer—an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009
|
Adam, R.
|
|
|
21 |
8 |
p. 1579-1584
|
artikel
|
Tijdschrift beschrijving